Key insights
- Whitehawk Therapeutics presented positive preclinical data on three ADC candidates at AACR, showing tumor regressions in various cancer models. The company's stock has surged, reflecting investor optimism. While early-stage, positive data in oncology can boost sentiment, the impact on broader US equities is limited unless the company becomes a takeover target or the technology is broadly disruptive.
MORRISTOWN, N.J. - Whitehawk Therapeutics (NASDAQ:WHWK) presented preclinical data for three antibody drug conjugate candidates at the American Association for Cancer Research Annual Meeting 2026, held April 17-22 in San Diego, according to a press release statement.The announcement comes as the stock has surged 162% over the past year and trades near its 52-week high of $4.48, reflecting investor enthusiasm for the company’s pipeline progress. With a market capitalization of $194 million, the clinical-stage biotech holds more cash than debt on its balance sheet, according to InvestingPro data.
The data covered HWK-007, HWK-016 and HWK-206, all utilizing the company’s Carbon Bridge Cysteine Re-pairing platform. The compounds demonstrated tumor regressions in various cancer models at low single-digit mg/kg doses.
HWK-007 targets PTK7, a tumor marker present in approximately 70% of tumors. The compound showed tumor regressions at doses as low as 1 mg/kg in small cell lung cancer and ovarian cancer models. In non-human primates, the highest non-severely toxic dose was 60 mg/kg. Free payload in circulation measured 0.0067% AUC. A Phase 1 trial is ongoing for patients with non-squamous, EGFR wild-type non-small cell lung cancer, platinum-resistant ovarian cancer and endometrial cancer.
HWK-016 targets the non-shed extracellular domain of MUC16 to avoid binding to circulating CA125. The compound produced tumor regressions at doses as low as 1 mg/kg in ovarian cancer xenograft models. The highest non-severely toxic dose in non-human primates was 60 mg/kg, with free payload below 0.01% AUC. A Phase 1 trial is ongoing in patients with advanced ovarian and endometrial cancers.
HWK-206 uses a biparatopic antibody targeting SEZ6. The compound showed tumor regressions at doses as low as 2 mg/kg in small cell lung cancer models. The highest non-severely toxic dose in non-human primates was 60 mg/kg, with free payload at 0.01% AUC. The company plans to submit an Investigational New Drug application in mid-2026 and initiate a Phase 1 trial in the third quarter of 2026.
The three assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
In other recent news, Whitehawk Therapeutics has been the focus of several notable developments. Citizens initiated coverage on Whitehawk Therapeutics with a Market Outperform rating, setting a price target of $8.00. This evaluation was based on a cash per share and platform value analysis, highlighting the company’s potential in developing antibody-drug conjugates. In addition, Whitehawk Therapeutics presented data at the Society of Gynecologic Oncology 2026 Annual Meeting, showcasing MUC16 expression patterns in ovarian and endometrial cancers. The analysis, conducted with Tempus AI, revealed that MUC16 expression in ovarian cancer is significantly higher than other antibody-drug conjugate targets. This protein showed stable expression across various disease stages and conditions in high-grade serous ovarian carcinoma, which is predominant in ovarian cancer cases. These recent developments underscore Whitehawk’s ongoing efforts in advancing its therapeutic platforms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.